Stocks and Investing Stocks and Investing
Mon, November 11, 2019
Fri, November 8, 2019
Thu, November 7, 2019
Wed, November 6, 2019

Andrew Berens Maintained (BPMC) at Buy with Decreased Target to $108 on, Nov 6th, 2019


Published on 2024-10-26 17:53:34 - WOPRAI
  Print publication without navigation


Andrew Berens of Morgan Stanley, Maintained "Blueprint Medicines Corporation" (BPMC) at Buy with Decreased Target from $109 to $108 on, Nov 6th, 2019.

Andrew has made no other calls on BPMC in the last 4 months.



There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 2 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Konstantinos Aprilakis of "Deutsche Bank" Downgraded from Strong Buy to Hold and Decreased Target to $75 on, Tuesday, October 29th, 2019
  • Christopher Raymond of "Piper Sandler" Initiated at Hold and Held Target at $85 on, Thursday, August 29th, 2019


These are the ratings of the 2 analyists that currently disagree with Andrew


  • Andrew Fein of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $100 on, Thursday, October 3rd, 2019
  • Joel Beatty of "Baird" Initiated at Buy and Held Target at $120 on, Friday, July 19th, 2019